Collaborative Arrangements and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2020 and 2019, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended March 31,
	2020			2019
SPINRAZA royalties (commercial revenue)	$	66.0		$	59.7
R&D revenue		21.4			24.5
Total revenue from our relationship with Biogen	$	87.4		$	84.2
Percentage of total revenue		66	%		28	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2020 and 2019, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Three Months Ended March 31,
	2020			2019
R&D revenue	$	13.8		$	4.0
Percentage of total revenue		10	%		1	%